The high production cost of biopharmaceuticals is an undeniable fact, and the "cost center" is clearly the downstream purification stage. According to industry data, downstream processing accounts for a significant portion of the total cost of biopharmaceutical production. More than 60% In some complex therapies, the proportion is even higher. With increasing pressure on drug prices from global payers and fierce competition from biosimilars, overcoming the cost challenges of downstream purification has become crucial for the survival and profitability of pharmaceutical companies.
Expensive "columns": Chromatography costs are the core pain point
Technological Breakthrough: From "Pre-assembled Columns" to "Continuous Flow"
To address these challenges, a range of innovative technologies and models are being widely adopted:
The Rise of Pre-packed Columns This "plug-and-play" solution is becoming a new industry trend. Pre-filled columns are pre-filled and quality-tested by the supplier in a controlled environment, meeting GMP standards, eliminating the need for users to install and validate the columns themselves. This not only eliminates human errors and batch-to-batch variations during column packing, improves product yield and result reproducibility, but also saves a significant amount of time and shortens the drug development cycle. For CDMOs (Contract Development and Manufacturing Organizations) that produce multiple drugs, pre-filled columns offer the flexibility for rapid process changeovers.
Benefits of continuous multi-column chromatography Traditional batch chromatography has low resin utilization. Continuous multi-column chromatography technology can reduce resin usage by 50% and significantly lower buffer consumption through multi-column series connection and simulated counter-current movement. This significantly reduces buffer consumption. Although the system is more complex to automate and requires professional personnel, its advantages in increasing output per unit area and reducing unit product cost are becoming increasingly apparent, and it is being adopted by more and more projects.
Advances in filtration technology:Novel filtration equipment such as depth filtration reduces operational steps and improves equipment productivity by combining clarification and fine filtration into a single system.
Traditional self-packed columns vs. pre-packed columns: a comparison
| Comparison Dimensions | Traditional self-installing columns | Pre-packed chromatographic column |
|---|---|---|
| Preliminary preparations | Resin has to be purchased, packed into columns, and tested and validated manually, which takes several days to weeks. | Ready-to-use, eliminating all column packing and validation time. |
| consistency | Affected by the operator's technical proficiency, column performance may vary between different batches. | Standardized production in the factory ensures high consistency in performance between batches. |
| Cross-contamination risk | The hardware on the column needs to be cleaned and reused, which poses a potential risk of cross-contamination. | Usually for single-use or equipped with a dedicated cartridge, minimizing contamination. |
| Technical barriers and costs | It requires a professional team and specialized equipment, resulting in high hidden human and time costs. | Reducing reliance on dedicated column packing technology may lower the total cost of ownership. |
| flexibility | Adjusting column size or resin type involves complex processes. | Columns of different specifications and packing materials can be quickly switched according to process requirements. |
The Game Between Outsourcing and Supply Chain
Faced with high fixed asset investments and technological complexity, an increasing number of companies are choosing to outsource downstream production to CDMOs (Contract Development and Manufacturing Organizations). By handling orders from multiple clients, CDMOs can amortize equipment investment costs and accumulate cross-product process experience. Meanwhile, to ensure supply chain security, pharmaceutical companies and CDMOs are implementing a "dual-supplier" strategy, seeking secondary sources for key consumables such as filters, bags, and resins. This has objectively created market opportunities for competitive new suppliers.
in conclusion :Cost-Reduction Campaign for Downstream Purification: Parallel Advancement of Technological Innovation and Model Optimization
As the core cost center accounting for over 60% of biologic drug production costs, downstream purification—plagued by expensive chromatographic consumables, complex operations, and supply chain dependence—has become a key pain point for pharmaceutical companies facing drug price pressure and market competition. To address this challenge, the industry is leveraging both technological innovation and model optimization: pre-packed chromatography columns enable "plug-and-play" functionality, simplifying processes and improving consistency; upgrades in continuous multi-column chromatography and filtration technologies effectively reduce consumable and time costs; meanwhile, the CDMO outsourcing model amortizes fixed asset investments, and the "dual-supplier" strategy ensures supply chain security and expands market opportunities. In summary, the cost-reduction drive for biologic downstream purification is not a breakthrough in a single link, but a comprehensive transformation covering technological innovation, model innovation, and supply chain optimization. Only through multi-dimensional collaborative efforts can pharmaceutical companies reduce costs, enhance competitiveness, and promote the continuous improvement of drug accessibility.
